672 related articles for article (PubMed ID: 27068454)
41. The Plasmodium yoelii microgamete surface antigen (PyMiGS) induces anti-malarial transmission blocking immunity that reduces microgamete motility/release from activated male gametocytes.
Tachibana M; Ishino T; Tsuboi T; Torii M
Vaccine; 2018 Nov; 36(49):7463-7471. PubMed ID: 30420038
[TBL] [Abstract][Full Text] [Related]
42. A recombinant Bacille Calmette-Guérin construct expressing the Plasmodium falciparum circumsporozoite protein enhances dendritic cell activation and primes for circumsporozoite-specific memory cells in BALB/c mice.
Arama C; Waseem S; Fernández C; Assefaw-Redda Y; You L; Rodriguez A; Radošević K; Goudsmit J; Kaufmann SH; Reece ST; Troye-Blomberg M
Vaccine; 2012 Aug; 30(37):5578-84. PubMed ID: 21983157
[TBL] [Abstract][Full Text] [Related]
43. T-cell recognition of a cross-reactive antigen(s) in erythrocyte stages of Plasmodium falciparum and Plasmodium yoelii: inhibition of parasitemia by this antigen(s).
Lucas B; Engels A; Camus D; Haque A
Infect Immun; 1993 Nov; 61(11):4863-9. PubMed ID: 8104901
[TBL] [Abstract][Full Text] [Related]
44. Immunogenicity of Plasmodium yoelii merozoite surface protein 4/5 produced in transgenic plants.
Wang L; Webster DE; Campbell AE; Dry IB; Wesselingh SL; Coppel RL
Int J Parasitol; 2008 Jan; 38(1):103-10. PubMed ID: 17681344
[TBL] [Abstract][Full Text] [Related]
45. Bridging Computational Vaccinology and Vaccine Development Through Systematic Identification, Characterization, and Downselection of Conserved and Variable Circumsporozoite Protein CD4 T Cell Epitopes From Diverse
Noe AR; Terry FE; Schanen BC; Sassano E; Hindocha P; Phares TW; Moise L; Christen JM; Tucker KD; Kotraiah V; Drake DR; Martin WD; De Groot AS; Gutierrez GM
Front Immunol; 2021; 12():689920. PubMed ID: 34168657
[TBL] [Abstract][Full Text] [Related]
46. Assessment of genetic diversity of Plasmodium falciparum circumsporozoite protein in Sudan: the RTS,S leading malaria vaccine candidate.
Mohamed NS; AbdElbagi H; Elsadig AR; Ahmed AE; Mohammed YO; Elssir LT; Elnour MB; Ali Y; Ali MS; Altahir O; Abubakr M; Siddig EE; Ahmed A; Omer RA
Malar J; 2021 Nov; 20(1):436. PubMed ID: 34758827
[TBL] [Abstract][Full Text] [Related]
47. Identification of a nonameric H-2Kk-restricted CD8+ cytotoxic T lymphocyte epitope on the Plasmodium falciparum circumsporozoite protein.
Malik A; Houghten R; Corradin G; Buus S; Berzofsky JA; Hoffman SL
Infect Immun; 1995 May; 63(5):1955-9. PubMed ID: 7537251
[TBL] [Abstract][Full Text] [Related]
48. Rhop-3 protein conservation among Plasmodium species and induced protection against lethal P. yoelii and P. berghei challenge.
Wang T; Fujioka H; Drazba JA; Sam-Yellowe TY
Parasitol Res; 2006 Aug; 99(3):238-52. PubMed ID: 16541261
[TBL] [Abstract][Full Text] [Related]
49. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.
Ophorst OJ; Radosević K; Havenga MJ; Pau MG; Holterman L; Berkhout B; Goudsmit J; Tsuji M
Infect Immun; 2006 Jan; 74(1):313-20. PubMed ID: 16368986
[TBL] [Abstract][Full Text] [Related]
50. A new malaria antigen produces partial protection against Plasmodium yoelii challenge.
Zhang Y; Qi Y; Li J; Liu S; Hong L; Lin T; Long C; Su XZ
Parasitol Res; 2012 Apr; 110(4):1337-45. PubMed ID: 21915626
[TBL] [Abstract][Full Text] [Related]
51. Generation and functional characterisation of Plasmodium yoelii csp deletion mutants using a microhomology-based CRISPR/Cas9 method.
Xu R; Liu Y; Fan R; Liang R; Yue L; Liu S; Su XZ; Li J
Int J Parasitol; 2019 Aug; 49(9):705-714. PubMed ID: 31202685
[TBL] [Abstract][Full Text] [Related]
52. Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of Plasmodium yoelii liver stage-infected hepatocytes.
Trimnell A; Takagi A; Gupta M; Richie TL; Kappe SH; Wang R
J Immunol; 2009 Nov; 183(9):5870-8. PubMed ID: 19812194
[TBL] [Abstract][Full Text] [Related]
53. Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein.
Wang LT; Pereira LS; Kiyuka PK; Schön A; Kisalu NK; Vistein R; Dillon M; Bonilla BG; Molina-Cruz A; Barillas-Mury C; Tan J; Idris AH; Francica JR; Seder RA
PLoS Pathog; 2021 Dec; 17(12):e1010133. PubMed ID: 34871332
[TBL] [Abstract][Full Text] [Related]
54. Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus.
Oliveira-Ferreira J; Miyahira Y; Layton GT; Savage N; Esteban M; Rodriguez D; Rodriguez JR; Nussenzweig RS; Zavala F
Vaccine; 2000 Mar; 18(17):1863-9. PubMed ID: 10699335
[TBL] [Abstract][Full Text] [Related]
55. Multiple antigen constructs (MACs): induction of sterile immunity against sporozoite stage of rodent malaria parasites, Plasmodium berghei and Plasmodium yoelii.
Reed RC; Louis-Wileman V; Cosmai EV; Fang S; Jue DL; Wohlhueter RM; Hunter RL; Lal AA
Vaccine; 1997 Apr; 15(5):482-8. PubMed ID: 9160515
[TBL] [Abstract][Full Text] [Related]
56. Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs.
Murugan R; Scally SW; Costa G; Mustafa G; Thai E; Decker T; Bosch A; Prieto K; Levashina EA; Julien JP; Wardemann H
Nat Med; 2020 Jul; 26(7):1135-1145. PubMed ID: 32451496
[TBL] [Abstract][Full Text] [Related]
57. Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice.
Aly AS; Downie MJ; Mamoun CB; Kappe SH
Cell Microbiol; 2010 Jul; 12(7):930-8. PubMed ID: 20088947
[TBL] [Abstract][Full Text] [Related]
58. Human antibodies against Plasmodium falciparum liver-stage antigen 3 cross-react with Plasmodium yoelii preerythrocytic-stage epitopes and inhibit sporozoite invasion in vitro and in vivo.
Brahimi K; Badell E; Sauzet JP; BenMohamed L; Daubersies P; Guérin-Marchand C; Snounou G; Druilhe P
Infect Immun; 2001 Jun; 69(6):3845-52. PubMed ID: 11349050
[TBL] [Abstract][Full Text] [Related]
59. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection.
Narum DL; Ogun SA; Thomas AW; Holder AA
Infect Immun; 2000 May; 68(5):2899-906. PubMed ID: 10768987
[TBL] [Abstract][Full Text] [Related]
60. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.
Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S
PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
